spike protein Archives - Amazing Health Advances

Yale Study Finds Spike Proteins from COVID Jabs Persist for TWO YEARS: Are mRNA Vaccines Rewriting Human DNA?

The AHA! Team — Mon, 17 Feb 2025 06:06:15 +0000

Lance D Johnson via Natural News – Researchers find spike proteins in vaccinated individuals TWO YEARS after inoculation. Yale scientists find COVID spike protein in vaccinated individuals up to two years post-vaccination. Study suggests mRNA genetic material may integrate with human DNA, activating protein-making structures. Renowned scientist Dr. Akiko Iwasaki, who initially supported mRNA vaccines, now leads the study. Vaccine skeptics warn of DNA contamination risks, citing evidence of self-replicating mRNA and reverse transcription. Research reveals mRNA vaccines may induce chronic inflammation, blood clotting, and neurological damage. Findings challenge claims of temporary, localized mRNA effects, raising concerns about long-term health impacts. Evidence suggests vaccinated individuals may become “super spreaders” of spike proteins, potentially endangering public health. Researchers find spike proteins in vaccinated individuals TWO YEARS after inoculation Scientists are raising alarms about the long-term consequences of these experimental COVID-19 injections. New findings from Yale University suggest that the genetic material in mRNA vaccines may not only persist in the human body but could also integrate with human DNA, fundamentally altering our genetic code. This disturbing discovery has profound implications for the health of billions of people worldwide and raises urgent questions about the ethics and safety of mRNA vaccine technology. Yale researchers have identified COVID spike proteins in the blood of vaccinated individuals — up to two years after they received their shots. Crucially, these individuals were never infected with the virus, as confirmed by antibody tests. The immune system typically destroys newly produced spike proteins, but the persistence of these proteins suggests that some vaccinated individuals may be producing them independently. A plausible explanation is that the genetic material delivered by the vaccines has integrated with human genes, activating protein-making structures within cells. If confirmed, this would mark a seismic shift in our understanding of mRNA vaccine safety. The implications of this discovery are staggering. More than a billion people worldwide have received mRNA COVID vaccines, and the possibility that these vaccines are altering human DNA is a game-changer. The consequences could extend far beyond the immediate health risks of Covid-19, potentially leading to chronic inflammation, autoimmune disorders, and long-term organ damage. The spike proteins produced by these vaccines are not benign; they are known to cause blood clotting, neurological inflammation, and even prion-like formations in the brain, which are linked to Alzheimer’s disease. The lead researcher on this groundbreaking study is Dr. Akiko Iwasaki, a renowned immunologist and former president of the American Association of Immunologists. Dr. Iwasaki was once a vocal advocate for mRNA vaccines, dismissing concerns about their safety as “absurd.” However, her team’s findings now suggest that those concerns may have been valid all along. The study, known as LISTEN, began in 2022 and has enrolled approximately 3,000 participants who reported post-vaccine injuries. The researchers have found spike proteins in participants’ blood samples more than 700 days after their last mRNA shot, a finding that challenges the narrative of temporary, localized mRNA effects. Welcome to the dark side of transhumanism The possibility of genetic integration is not a new concern among vaccine skeptics. Some researchers have long warned that the mRNA vaccines could contaminate human DNA, a process known as “transfection.” The manufacturing process of mRNA vaccines involves the use of DNA plasmids, which can lead to small amounts of DNA contamination in the final product. While federal standards limit allowable DNA contamination to 10 nano grams per dose, the lipid nanoparticles used to protect the mRNA may also shield the DNA contaminants, potentially allowing them to integrate into human genes. Recent research by Kevin McKernan and others has provided further evidence of DNA contamination in vaccine vials, raising questions about the adequacy of current regulatory standards. Dr. Richard M. Fleming, a nuclear cardiologist, has also warned that mRNA vaccines are self-replicating and may turn individuals into “never-ending spike protein factories.” His research suggests that the genetic sequence for SARS-CoV-2 is designed to self-assemble and self-amplify, integrating into human DNA through reverse transcription. This process could hijack healthy genetic expression, leading to chronic inflammation and organ damage for years to come. The consequences of these findings are nothing short of alarming. Vaccinated individuals may not only suffer long-term health consequences but could also become “super spreaders” of spike proteins, potentially endangering public health for generations. The idea that mRNA vaccines could rewrite human DNA and turn individuals into perpetual bioweapon vectors is a chilling prospect, one that aligns with the emerging field of transhumanism. As genetic updates become the norm, the line between human and machine blurs, raising ethical questions about autonomy, consent, and the future of humanity. Sources include: AlexBerensen.substack.com Medicine.Yale.edu NaturalNews.com To read the original article, click here

The post Yale Study Finds Spike Proteins from COVID Jabs Persist for TWO YEARS: Are mRNA Vaccines Rewriting Human DNA? appeared first on Amazing Health Advances.

FDA: Merck COVID Pill Effective, Experts Will Review Safety

AHA Publisher — Wed, 01 Dec 2021 08:00:16 +0000

Matthew Perrone via CBN News – Federal health regulators say an experimental COVID-19 pill from Merck is effective against the virus, but they will seek input from outside experts on risks of birth defects and other potential problems during pregnancy. The Food and Drug Administration posted its analysis of the pill ahead of a public meeting next week where academic and other experts will weigh in on its safety and effectiveness. The agency isn’t required to follow the group’s advice. The FDA scientists said their review identified several potential risks, including possible toxicity to developing fetuses and birth defects that were identified in studies of the pill in animals. Given those risks, the FDA will ask its advisers next Tuesday whether the drug should never be given during pregnancy or whether it could be made available in certain cases. Under that scenario, the FDA said the drug would carry warnings about risks during pregnancy, but doctors would still have the option to prescribe it in certain cases where its benefits could outweigh its risks for patients. Given the safety concerns, FDA said Merck agreed the drug would not be used in children. Other side effects were mild and rare, with about 2% of patients experiencing diarrhea. Regulators also noted that Merck collected far less safety data overall on its drug than was gathered for other COVID-19 therapies. “While the clinical safety database was small, there were no major safety concerns identified,” FDA reviewers concluded. Additionally, the FDA flagged a concern that Merck’s drug led to small changes in the coronavirus’ signature spike protein, which it uses to penetrate human cells. Theoretically, FDA cautioned, those changes could lead to dangerous new variants. FDA will ask its independent advisers to discuss all those issues and then vote on whether the drug’s overall benefits outweigh its risks. All COVID-19 drugs currently authorized by the FDA require an injection or IV and can only be given by health professionals. If authorized, Merck’s drug would be the first that U.S. patients could take at home to ease symptoms and speed recovery. It is already authorized for emergency use in the U.K. The meeting marks the first time regulators have publicly reviewed a new drug for COVID-19, reflecting the intense interest and scrutiny of a pill that could be soon used by millions of Americans. The drug, molnupiravir, has been shown to significantly cut the rate of hospitalizations and deaths among people with mild-to-moderate coronavirus infections. Merck’s drug uses a novel approach to fight COVID-19: it inserts tiny mutations into the coronavirus’ genetic code to stop the virus from reproducing. But that genetic effect has raised concerns that in rare cases the drug could cause birth defects or even spur more virulent strains of the virus. Pregnant women were excluded from Merck’s study, and both women and men in the study were instructed to use contraception or abstain from sex. For its part, Merck says results from two company studies in rodents show the drug does not cause mutations or damage to DNA at the doses studied. FDA reviewers also confirmed previously reported interim results from Merck that the pill cut the rate of hospitalization and death by about half among patients with early symptoms of COVID-19 who faced increased risk due to health problems. However, on Friday morning Merck announced updated results from the same study that showed a smaller benefit from the drug. The FDA said it is still reviewing the updated data and would present a new assessment of the drug’s effectiveness next Tuesday. Among more than 1,400 adults in a company study, molnupiravir reduced the combined risk of hospitalization and death by 30%, less than the 50% initially reported based on incomplete results. Nearly 7% of patients who received Merck’s drug within five days of COVID-19 symptoms ended up in the hospital and one died. That compared to 10% of patients hospitalized who were taking the placebo and nine deaths. Merck didn’t study its drug in people who were vaccinated for COVID-19. But the FDA will ask advisers to recommend which patients may stand to benefit the most from the drug, based on vaccination status and underlying health problems. While Merck’s drug is likely to be the first pill for coronavirus in the U.S., more are expected to follow. Rival drugmaker Pfizer has submitted its own antiviral for FDA review after initial study results showed it cut the combined rate of hospitalization and death by nearly 90%. Pfizer’s drug is part of a decades-old family of antiviral pills known as protease inhibitors, which revolutionized the treatment of HIV and hepatitis C. They work differently than Merck’s pill and haven’t been linked to the kind of mutation concerns that have been raised with Merck’s drug. To read the original article click here.

The post FDA: Merck COVID Pill Effective, Experts Will Review Safety appeared first on Amazing Health Advances.

Cannabis Compound Inhibits SARS-CoV-2 Replication in Human Lung Cells

AHA Publisher — Mon, 22 Mar 2021 07:00:34 +0000

Sally Robertson, B.Sc. via New-Medical – Researchers in the United States have conducted a study showing that a cannabis plant compound inhibited infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human lung cells. SARS-CoV-2 is the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic that continues to sweep the globe posing a threat to global public health and the worldwide economy. Marsha Rosner from the University of Chicago in Illinois and colleagues found that cannabidiol (CBD) and its metabolite 7-OH-CBD potently blocked SARS-CoV-2 replication in lung epithelial cells. The CBD inhibited viral gene expression and reversed many of the effects the virus has on host gene transcription. The compound also induced the expression of interferons – cell signaling proteins that are produced by host cells as an early response to viral invasion. Furthermore, the incidence of SARS-CoV-2 infection was up to an order of magnitude lower in a cohort of patients who had been taking CBD, compared with matched patients who had not been taking CBD. “This study highlights CBD, and its active metabolite, 7-OH-CBD, as potential preventative agents and therapeutic treatments for SARS-CoV-2 at early stages of infection,” says Rosner and the team. A pre-print version of the research paper is available on the bioRxiv* server, while the article undergoes peer review. Rapid Spread of SARS-CoV-2 Highlights the Need for New Treatments Since the COVID-19 outbreak first began in Wuhan, China, in late December 2019, the rapid spread of SARS-CoV-2 has led to more than 119.5 million infections and caused more than 2.64 million deaths. Although recently-approved vaccines are now being rolled out in many countries, the virus is still spreading rapidly. Rosner and colleagues say this highlights the need for alternative approaches, particularly among populations with limited access to vaccines. However, “to date, few therapies have been identified that block SARS-CoV-2 replication and viral production,” write the researchers. More About SARS-CoV-2 and CBD The SARS-CoV-2 virus primarily enters host cells through the binding of a surface viral protein called spike to the human host cell receptor angiotensin-converting enzyme 2 (ACE2). The viral genome is then translated into two large polypeptides that are cleaved by the viral proteases MPro and PLPro to produce the proteins required for viral replication, assembly, and budding. Rosner and colleagues say that, although limited, some studies have reported that certain cannabinoids have antiviral effects against hepatitis C virus and other viruses. Furthermore, an oral solution of CBD is already approved by the US food and Drug Administration for the treatment of epilepsy. What Did the Current Study Involve? To test the effect of CBD on SARS-CoV-2 replication, the researchers pretreated A549 human lung carcinoma cells expressing ACE-2 (A549-ACE2) with 0-10μM CBD for 2 hours before infecting them with SARS-CoV-2. Analysis of the cells 48 hours later showed that CBD had potently inhibited viral replication in the cells. Since CBD is often consumed as part of a Cannabis sativa extract, the team investigated whether other cannabinoids could also inhibit SARS-CoV-2 infection, especially those with closely related structures. Remarkably, the only agent that potently inhibited viral replication was CBD; limited or no antiviral activity was exhibited by the other structurally similar cannabinoids tested. Furthermore, the CBD metabolite 7-OH-CBD, the active ingredient in the CBD treatment of epilepsy, also effectively inhibited SARS-CoV-2 replication in the A549-ACE2 cells. CBD Effectively Eliminated Viral RNA Expression When the researchers assessed whether CBD might prevent proteolytic cleavage by Mpro or PLpro, they found CBD had no effect on the activity of either protease. This led the team to hypothesize that CBD targets host cell processes. Consistent with this hypothesis, RNA sequencing of infected A549-ACE2 cells treated with CBD for 24 hours revealed significant suppression of SARS-CoV-2-induced changes in gene expression. The CBD effectively eliminated viral RNA expression, including RNA coding for the spike protein. Both SARS-CoV-2 and CBD triggered significant changes in cellular gene expression, including the expression of several transcription factors. Further analysis of host cell RNA showed that the virus-induced changes were almost completely reversed, but rather than the cells returning to a normal cell state, the CBD+virus-infected cells resembled those treated with CBD alone. What About Interferon Signaling? Given that infection with SARS-CoV-2 is known to suppress the interferon signaling pathway, the researchers tested whether CBD could suppress viral infection by introducing this pathway. Some genes were induced by CBD in both the absence and presence of SARS-CoV-2, including genes that encode interferon receptors and mediators of the interferon signaling pathway. In addition, CBD effectively reversed the viral induction of cytokines that can trigger a deadly hyperinflammatory response called the “cytokine storm” during the later stages of infection. “Thus, CBD has the potential not only to act as an antiviral agent at early stages of infection but also to protect the host against an overactive immune system at later stages,” says Rosner and the team. SARS-CoV-2 Incidence Was Lower in Patients Who Took CBD Finally, the team assessed the incidence of SARS-CoV-2 infection among 82 patients who had been prescribed CBD prior to SARS-C0V-2 testing and matched patients who had not been prescribed CBD. Strikingly, the incidence of SARS-CoV-2 was only 1.2% among the patients prescribed CBD, compared with 12.2% among the matched patients who had not been taking CBD. “The substantial reduction in SARS-CoV-2 infection risk of approximately an order of magnitude in patients who took FDA-approved CBD highlights the potential efficacy of this drug in combating SARS-CoV2 infection,” says Rosner and colleagues. “We advocate carefully designed placebo-controlled clinical trials with known concentrations and highly-characterized formulations in order to define CBD’s role in preventing and treating early SARS-CoV-2 infection,” they conclude. *Important Notice bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information. To read the original article click here.

The post Cannabis Compound Inhibits SARS-CoV-2 Replication in Human Lung Cells appeared first on Amazing Health Advances.

Lab Study Reveals Effective Treatment for COVID-19

AHA Publisher — Mon, 18 Jan 2021 08:00:22 +0000

Rush University Medical Center via News-Medical Net – A new potential therapy for COVID-19 developed by researchers at Rush University Medical Center has shown success in preventing the disease’s symptoms in mice. In a study, mouse models with COVID-19 showed positive results when a peptide (chain of amino acids) was introduced nasally. The peptide proved effective in reducing fever, protecting the lungs, improving heart function and reversing cytokine storm -; the immune system overreacting to an infection and flooding the bloodstream with inflammatory proteins. The researchers also report success in preventing the disease from progression in the report of their results published Jan. 11 in the Journal of Neuroimmune Pharmacology. SARS-CoV-2, the virus that causes COVID-19, binds to an enzyme called ACE2 to enter and infect human cells. In response, the research team designed a hexapeptide (a peptide with six amino acids) that inhibits the virus from binding with ACE2. “This could be a new approach to prevent SARS-CoV-2 infection and protect COVID-19 patients from breathing problems and cardiac issues,” said Kalipada Pahan, PhD, the Floyd A. Davis Professor of Neurology at the Rush University Medical Center and a research career scientist at the Jesse Brown VA Medical Center, who led the study. Many patients with COVID-19 in intensive care units suffer from cytokine storm, which affects lungs, heart and other organs. Although anti-inflammatory therapies such as steroids are available to treat the problem, very often these treatments cause suppression of the immune system. The peptide inhibits cytokines that only are produced by the SARS-CoV-2 spike protein, not other inflammatory stimuli, indicating that this peptide would not cause immunosuppression.” (Kalipada Pahan, PhD, Floyd A. Davis Professor of Neurology, Rush University Medical Center) Although vaccines for COVID-19 are becoming available, their distribution nationally and globally will take months and possibly years in some part of the world. In addition, vaccines may not entirely prevent the spread of COVID-19. For example, despite flu vaccination, about 40,000 to 50,000 people die each year in United States from the flu. Therefore, a specific medicine for reducing inflammatory events and treating respiratory and cardiac problems caused by COVID-19 will be necessary for better management of the disease even in the post-vaccine era. “If our peptide results can be replicated in COVID-19 patients, it would be a remarkable advance in controlling this devastating pandemic,” Pahan said. To read the original article click here.

The post Lab Study Reveals Effective Treatment for COVID-19 appeared first on Amazing Health Advances.

Compounds in Traditional Chinese Medicine Herbs May Inhibit SARS-CoV-2 Infection

AHA Publisher — Fri, 04 Dec 2020 08:00:05 +0000

Lakshmi Supriya, PhD. via News-Medical Net – Using computational methods, a team of researchers identified three compounds in traditional Chinese medicine that could be used against SARS-CoV-2: quercetin, puerarin and kaempferol. Of the three compounds, quercetin showed the highest binding affinity to both the ACE2 receptor and the receptor-binding domain of the SARS-CoV-2 spike protein, and could thus provide a dual synergistic effect. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of the ongoing coronavirus disease 2019 (COVID-19) pandemic, infects human hosts by binding with the human angiotensin-converting enzyme 2 (ACE2) receptor on their cells, notably the epithelium lining the respiratory tract. The receptor-binding domain (RBD) of the coronavirus spike protein binds to ACE2 followed by membrane fusion to the host cell, thus allowing the virus to infiltrate the cell and commence replication. Traditional Chinese medicine, widely used for many diseases, showed therapeutic effects during the 2003 SARS-CoV epidemic. The RBD of the SARS-CoV-2 has significant structural homology with SARS-CoV. Although the use of Chinese herbs with modern medicine has shown benefits in COVID-19 patients, several components are present in the herbs and have complex interactions, making it challenging to uncover the molecular mechanisms responsible for its therapeutic effects. Several computational studies have helped predict active compounds in the medicinal herbs with the potential to accelerate traditional medicine-based drug discovery. Finding Potential Compounds Against SARS-CoV-2 Researchers from various institutions in China used computational analysis to discover potential molecule candidates against SARS-CoV-2 infection. Using the Traditional Chinese Medicine Pharmacology database, they screened for molecules that could target ACE2. They identified the compound puerarin that could target ACE2. Then, they screened for Chinese herbs that have this compound in the database and found five. Furthermore, since it is thought that compounds in the same herbal medicine have synergistic properties, they expanded their search to include all the compounds in the five herbs to arrive at 41 compounds. Upon analyzing which compounds were present in the maximum number of herbs, they found puerarin was present in all the five herbs, and quercetin and kaempferol were present in three herbs. Next, they predicted potential drug targets of the selected compounds using the database, leading to 240 possible targets. Upon further analysis, they selected puerarin, quercetin, and kaempferol for further study. Next, the authors performed molecular docking analysis to determine potential binding sites and binding affinity to ACE2. All the three compounds could bind on the same region of ACE2, which is located some distance from the binding position of SARS-CoV-2. It is likely the compounds are causing changes in conformations rather than competing with the spike protein to bind to ACE2. Quercetin had the highest binding affinity, forming both strong and weak hydrogen bonds. They also experimentally determined the binding of the three compounds to ACE2 using surface plasmon resonance. Similar to the theoretical analysis, they found quercetin had higher binding affinity to ACE2 than puerarin. They also observed that puerarin affected the binding of spike protein to ACE2, and quercetin almost completely disrupted the spike protein binding to ACE2. Molecular docking analysis showed that quercetin has high binding affinity to the spike protein. Using pathway enrichment analysis for the COVID-19-related genes, they found quercetin affected the immune-modulation and viral infection activities. How the Compounds Affect SARS-CoV-2 All the three compounds tested were found in the herb Radix Bupleuri confirming that compounds in a single herb have synergistic pharmacological properties. The herb is popular in China and has been used to treat flu, inflammation, malaria, and hepatitis B. It is also one of 26 Chinese herbal medicines advised by traditional Chinese medicine practitioners to combat COVID-19. Puerarin has been approved for use in China for decades and could be an ideal drug repurposed for its antiviral properties. Although its binding affinity is lower than quercetin, it has a safe dose limit of about 0.5 gram, so it could be used at a high dose to achieve a suitable antiviral effect. It also has beneficial effects on fever, cardiovascular disease, and neurological dysfunction, so it can also be used as an adjuvant to help improve COVID-19 symptoms. Quercetin showed a higher binding affinity to both ACE2 and the RBD of the spike protein. The dual binding effect of quercetin could therefore be synergistic and provide a strong antiviral effect against SARS-CoV-2. Furthermore, since analysis suggested that quercetin could affect immunomodulation, and because studies have shown patients with severe COVID-19 disease tend to experience cytokine storms, quercetin could help alleviate symptoms in such cases. To read the original article click here.

The post Compounds in Traditional Chinese Medicine Herbs May Inhibit SARS-CoV-2 Infection appeared first on Amazing Health Advances.

Exposure to Common Cold Coronaviruses Can Teach the Immune System to Recognize SARS-CoV-2

AHA Publisher — Wed, 05 Aug 2020 07:00:24 +0000

La Jolla Institute for Immunology via EurekAlert – Your immune system’s “memory” T cells keep track of the viruses they have seen before. This immune cell memory gives the cells a headstart in recognizing and fighting off repeat invaders. Now, a new study led by scientists at La Jolla Institute for Immunology (LJI) shows that memory helper T cells that recognize common cold coronaviruses also recognize matching sites on SARS-CoV-2, the virus that causes COVID-19. The research, published Aug. 4, 2020 in Science, may explain why some people have milder COVID-19 cases than others–though the researchers emphasize that this is speculation and much more data is needed. “We have now proven that, in some people, pre-existing T cell memory against common cold coronaviruses can cross-recognize SARS-CoV-2, down to the exact molecular structures,” says LJI Research Assistant Professor Daniela Weiskopf, Ph.D., who co-led the new study with LJI Professor Alessandro Sette, Dr. Biol. Sci. “This could help explain why some people show milder symptoms of disease while others get severely sick.” “Immune reactivity may translate to different degrees of protection,” adds Sette. “Having a strong T cell response, or a better T cell response may give you the opportunity to mount a much quicker and stronger response.” The new work builds on a recent Cell paper from the Sette Lab and the lab of LJI Professor Shane Crotty, Ph.D., which showed that 40 to 60 percent of people never exposed to SARS-CoV-2 had T cells that reacted to the virus. Their immune systems recognized fragments of the virus it had never seen before. This finding turned out to be a global phenomenon and was reported in people from the Netherlands, Germany, the United Kingdom and Singapore. Scientists wondered if these T cells came from people who had previously been exposed to common cold coronaviruses–what Sette calls SARS-CoV-2’s “less dangerous cousins.” If so, was exposure to these cold viruses leading to immune memory against SARS-CoV-2? For the new study, the researchers relied on a set of samples collected from study participants who had never been exposed to SARS-CoV-2. They defined the exact sites of the virus that are responsible for the cross-reactive T cell response. Their analysis showed that unexposed individuals can produce a range of memory T cells that are equally reactive against SARS-CoV-2 and four types of common cold coronaviruses. This discovery suggests that fighting off a common cold coronavirus can indeed teach the T cell compartment to recognize some parts of SARS-CoV-2 and provides evidence for the hypothesis that common cold viruses can, in fact, induce cross-reactive T cell memory against SARS-CoV-2. “We knew there was pre-existing reactivity, and this study provides very strong direct molecular evidence that memory T cells can ‘see’ sequences that are very similar between common cold coronaviruses and SARS-CoV-2,” says Sette. Looking closer, the researchers found that while some cross-reactive T cells targeted the SARS-CoV-2’s spike protein, the region of the virus that recognizes and binds to human cells, pre-existing immune memory was also directed to other SARS-CoV-2 proteins. This finding is relevant, Sette explains, since most vaccine candidates target mostly the spike protein. These findings suggest the hypothesis that inclusion of additional SARS-CoV-2 targets might enhance the potential to take advantage of this cross reactivity and could further enhance vaccine potency. To read the original article click here.

The post Exposure to Common Cold Coronaviruses Can Teach the Immune System to Recognize SARS-CoV-2 appeared first on Amazing Health Advances.